[go: up one dir, main page]

WO2012068441A3 - Intedanib salts and solid state forms thereof - Google Patents

Intedanib salts and solid state forms thereof Download PDF

Info

Publication number
WO2012068441A3
WO2012068441A3 PCT/US2011/061352 US2011061352W WO2012068441A3 WO 2012068441 A3 WO2012068441 A3 WO 2012068441A3 US 2011061352 W US2011061352 W US 2011061352W WO 2012068441 A3 WO2012068441 A3 WO 2012068441A3
Authority
WO
WIPO (PCT)
Prior art keywords
intedanib
salts
solid state
state forms
forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/061352
Other languages
French (fr)
Other versions
WO2012068441A2 (en
Inventor
Wolfgang Albrecht
Dirk Fischer
Christian Janssen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ratiopharm GmbH
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Original Assignee
Ratiopharm GmbH
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm GmbH, Teva Pharmaceutical Industries Ltd, Teva Pharmaceuticals USA Inc filed Critical Ratiopharm GmbH
Publication of WO2012068441A2 publication Critical patent/WO2012068441A2/en
Publication of WO2012068441A3 publication Critical patent/WO2012068441A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides salts of Intedanib, crystalline forms of the salts of Intedanib, processes for their manufacture and their use in pharmaceutical compositions.
PCT/US2011/061352 2010-11-19 2011-11-18 Intedanib salts and solid state forms thereof Ceased WO2012068441A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10191913 2010-11-19
EP10191913.2 2010-11-19

Publications (2)

Publication Number Publication Date
WO2012068441A2 WO2012068441A2 (en) 2012-05-24
WO2012068441A3 true WO2012068441A3 (en) 2012-08-16

Family

ID=45094793

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/061352 Ceased WO2012068441A2 (en) 2010-11-19 2011-11-18 Intedanib salts and solid state forms thereof

Country Status (1)

Country Link
WO (1) WO2012068441A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104003925B (en) * 2013-06-05 2016-03-30 四川大学 Indolinone compound or its derivative and use thereof
CN104262232B (en) 2014-09-09 2016-05-04 苏州明锐医药科技有限公司 The preparation method of Ni Taidani
CN106008308A (en) * 2015-03-13 2016-10-12 正大天晴药业集团股份有限公司 Nintedanib ethanesulfonate crystal
CN104844499B (en) * 2015-06-05 2017-03-08 北京康立生医药技术开发有限公司 One kettle way prepares the synthetic method of Nintedanib
CZ308695B6 (en) * 2015-07-29 2021-03-03 Zentiva, K.S. Process for preparing methyl (Z) -3 - [[4- [methyl [2- (4-methyl-1-piperazinyl) acetyl] amino] phenyl] amino] phenylmethylene) -oxindole-6-carboxylate (intedanib, nintedanib)
CN106432042A (en) * 2015-08-13 2017-02-22 南京华威医药科技开发有限公司 New medicine crystal form of nintedanib ethanesulfonate hydrate
CN106467500A (en) * 2015-08-14 2017-03-01 廊坊百瑞化工有限公司 A kind of one pot synthesis synthesize the new method of Nintedanib key intermediate
CN105418483A (en) * 2015-12-15 2016-03-23 南京艾德凯腾生物医药有限责任公司 Preparation method of crystalline nintedanib esylate
CZ2016104A3 (en) * 2016-02-24 2017-09-06 Zentiva, K.S. Crystalline modifications of methyl (3Z)-3- {[(4-{methyl[(4-methylpiperazin-1yl)acetyl]amino}phenyl)amino](phenyl)methylidene}-2oxo-2,3-dihydro-1H-indole-6-carboxylate and the methods of their preparation
CN105837493B (en) * 2016-04-08 2018-12-14 东南大学 The synthetic method and its intermediate of Nintedanib
US10836751B2 (en) 2016-10-12 2020-11-17 Zhejiang Huahai Pharmaceutical Co., Ltd. Methods for preparing Nintedanib and intermediates thereof
CN107935909B (en) * 2016-10-13 2023-03-17 上海科胜药物研发有限公司 Synthesis method of nintedanib and intermediate thereof
CN108610308A (en) * 2016-12-09 2018-10-02 上海奥博生物医药技术有限公司 The method that one kettle way prepares Nintedanib intermediate
CN111465594B (en) 2017-11-17 2023-11-07 费米有限公司 Synthesis of 2-Indolinone Known as Intermediate for the Preparation of Nintedanib
CN110746378B (en) * 2018-12-03 2021-11-05 江苏豪森药业集团有限公司 Preparation method of amino intermediate
CN111662223B (en) * 2019-03-08 2023-07-14 四川科伦药物研究院有限公司 Indolinone derivatives and process for preparing intermediates thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013099A1 (en) * 2002-07-24 2004-02-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition
WO2007141283A2 (en) * 2006-06-08 2007-12-13 Boehringer Ingelheim International Gmbh Salts and crystalline salt forms of an 2-indolinone derivative

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA75054C2 (en) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Substituted in position 6 indolinones, producing and use thereof as medicament
RU2525114C2 (en) 2007-12-03 2014-08-10 Бёрингер Ингельхайм Интернациональ Гмбх Method of obtaining indolinone derivative
PE20091445A1 (en) 2007-12-03 2009-10-19 Boehringer Ingelheim Int INDOLINONE DERIVATIVES AND PROCEDURE FOR ITS MANUFACTURE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013099A1 (en) * 2002-07-24 2004-02-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition
WO2007141283A2 (en) * 2006-06-08 2007-12-13 Boehringer Ingelheim International Gmbh Salts and crystalline salt forms of an 2-indolinone derivative

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BERGE ET AL.: "PHARMACEUTICAL SALTS", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, no. 1, 1 January 1977 (1977-01-01), pages 1 - 19, XP002552191, ISSN: 0022-3549, DOI: 10.1002/JPS.2600660104 *
STAHL ET AL. (ED.): "Handbook of Pharmaceutical Salts", 1 January 2002, WILEY-VCH, Weinheim, ISBN: 978-3-906390-26-0, article WERMUTH ET AL.: "Introduction", pages: 1 - 7, XP002421267 *

Also Published As

Publication number Publication date
WO2012068441A2 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
WO2012068441A3 (en) Intedanib salts and solid state forms thereof
IL269858A (en) Pyridone and aza-pyridone compounds, pharmaceutical composition and kits comprising the same and uses thereof
IL279304A (en) Cytotoxic benzodiazepine derivatives, compositions comprising the same and uses thereof
WO2010117738A3 (en) Solid state forms of sitagliptin salts
IL233154A (en) Compounds, pharmaceutical compositions comprising the same and uses thereof
IL224288A (en) Derivatives of substituted pyrazolamide, pharmaceutical compositions comprising the same and uses thereof
WO2011130615A3 (en) Preparation of lacosamide
WO2012087288A3 (en) Metal salt compositions
HUE037747T2 (en) Nanostructured aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them
IL216254A (en) Compounds, pharmaceutical compositions comprising the same and uses thereof
WO2012122383A3 (en) Pi3 kinase inhibitors and uses thereof
IL220863A (en) Oxazole kinase inhibitors, pharmaceutical compositions comprising them and uses thereof
WO2011098582A3 (en) Novel crystalline forms of ivabradine hydrochloride
WO2010092090A3 (en) Novel salts of sitagliptin
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
IL226270A0 (en) Hydroxamic acid derivatives, compositions comprising the same and uses thereof
EP2729464B8 (en) Cyclopropyl-fused-1,3-thiazepines as bace 1 and/or bace 2 inhibitors
PL2768936T3 (en) Formulations, their use as or for the manufacture of dishwashing compositions, and manufacture
IL223865A0 (en) Calcium salts of dihydrooroorotate dehydrogenase inhibitors, compositions comprising the same and uses thereof
HK1200314A1 (en) R(+)-n-methyl-propargyl-aminoindan
WO2012070062A3 (en) Novel polymorph of nilotinib hydrochloride
WO2014076712A3 (en) Lurasidone hydrochloride solid dispersion
WO2013055687A3 (en) R(+)-n-formyl-propargyl-aminoindan
WO2012137227A3 (en) Solid forms of antiretroviral compounds and anti-oxidative acids, processes for preparation and pharmaceutical compositions thereof
WO2012107890A3 (en) Crystal forms of lurasidone chlorhydrate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11791386

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11791386

Country of ref document: EP

Kind code of ref document: A2